MUNICH--(BUSINESS WIRE)--Definiens, the pioneer in Tissue Phenomics solutions for diagnostics development and commercialization, today announced the release of the Tissue Studio® 4.2 software package. The updated product suites provide improved image analysis functionality for scientists in academic medical centers, comprehensive cancer centers, and biotech and pharmaceutical companies so they can reach accurate conclusions to their research questions more quickly and efficiently.
Image analysis enables researchers to automate time consuming manual analysis, produces quantitative readouts that can be mined and correlated, and simplifies analysis tasks and workflows. Definiens Tissue Studio® is the leading image analysis solution for biomarker and morphological profiling in research and drug discovery on tissue samples. Through its unique ability to overcome inherent biological and staining variability, Tissue Studio® accurately detects regions of interest and distinguishes cell types and cell subtypes within target regions across any number of tissue slides.
New benefits available with Tissue Studio® 4.2 include:
- TMA brightness slider for improved TMA core detection: Users can now configure the TMA core detection for brightness variations in an image data set using a slider, minimizing and even eliminating the number of cores that traditionally require manual annotation. This improves efficiency and minimizes errors.
- Improved needle biopsy registration: Tissue Studio® 4.2 features improved automatic alignment for needle biopsies to allow more accurate transfer of the regions of interest between consecutive slides.
Tissue Studio® 4.2 also provides the ability to create powerful “Heat Maps” based on combinations of readouts and object features. Heat Maps allow a more sophisticated and efficient visual review of the local distribution of the biomarker expression, for example of immune cell populations in the tumor microenvironment.
“Tissue Studio® continues to lead the market in providing researchers with comprehensive and consistent data from their tissue-based assays,” said Merrilyn Datta, Chief Commercial Officer. “We are pleased to continue to offer the best software for quantitative image analysis.”
Definiens software suites provide labs with best-in-class performance and scalability, and deliver powerful and consistent results for research projects utilizing tissue. With these new updates, Tissue Studio® 4.2 enables researchers to analyze tissue and obtain more accurate results quickly and efficiently so they can complete a high volume of research projects in a shorter amount of time.
Licenses for previous versions of Definiens products will continue to function. However, current Tissue Studio® users can download the new releases by contacting support@definiens.com.
For a full list of features and to learn more about Definiens’ Tissue Studio®, visit www.definiens.com.
About Definiens
Definiens is the pioneering provider of Tissue Phenomics® solutions for biomarker and companion diagnostics development and commercialization. Definiens’ technology empowers smarter tissue-based diagnostics by leveraging quantitative tissue readouts and other big data sources. By enabling the development of powerful and precise assays for patient stratification and clinical trial enrollment, Definiens aims to dramatically improve patient outcomes. Definiens' Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit: www.definiens.com.